The Characteristics of Sociodemography, Histopathologic Features, Stage, and Management of Ovarian Cancer in Dr. Ramelan Navy Hospital Surabaya

Karina Rahmalia, Ketut Edy Sudiarta, Herin Setianingsih, Wienta Diarsvitri


Background: Ovarian cancer is considered a silent killer disease, mainly due to the late diagnosis. It is often diagnosed at an advanced stage, thus increasing the mortality rate. Ovarian cancer can happen to any age, with different characteristics according to the age group, the most often being the epithelial type.

Methods: This research is a descriptive study with a quantitative method. This study aims to determine the characteristics and histopathological features of ovarian cancer in Dr. Ramelan Navy Hospital from January 2019 to December 2021. There were 155 samples out of 635 patients, with the information acquired through medical records.

Results: The highest incidence of ovarian cancer occurs in the 40-60-year-old group at 52.9%. Among all participants, 85.8% of patients were not employed. Of most histopathological features in epithelial ovarian cancer, 34.8% were the serous carcinoma subtype. The majority of these cases were diagnosed at stage IIIC at 21.3%, and the most prevalent treatment for ovarian cancer was surgery and chemotherapy at 49.7%.

Conclusions: The most common type of ovarian cancer is epithelial ovarian cancer, a subtype of serous carcinoma, with histopathological features of round nucleated anaptic cells, prominent nucleoli, forming acini, papillae, and thin connective tissue stroma.



ovarian cancer, histopathological feature

Full Text: View | Download

DOI: 10.33371/ijoc.v18i2.1050

Article Metrics

Abstract View: 162,
PDF Download: 49


Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.

Ferlay J, Ervik M, Lam F, et al. Ovarian Cancer Incidence and Mortality. Lyon, France: International Agency for Research on Cancer [Internet]. 2024. Available from:

Zheng J, Sun Y, Long T, et al. Sonosensitizer nanoplatformmediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation. Drug Deliv. 2022;29(1):1164–75.

Harsono AB. Kanker Ovarium : “The Silent Killer.” Indonesian Journal of Obstetrics & Gynecology Science. 2020;3(1):1-6.

Bhattacharya S, Anjum MM, Patel KK. Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery. Drug Deliv. 2022;29(1):1060–74.

Debashis D, Nath LK. Ovarian Cancer-The Silent Killer. J Tumor Res. 2018;3:3.

Nersesian S, Glazebrook H, Toulany J, et al. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Front Immunol. 2019 Aug 9;10:1782.

Aqilla S, Harsono AB, Agustina H. Gambaran Klinis dan Histopatologi Kanker Ovarium di RSUP Dr. Hasan Sadikin Bandung Tahun 2019-2020. Indones J Obstet Gynecol Sci. 2022;5:27–35.

Greppi M, Tabellini G, Patrizi O, et al. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. Int J Mol Sci. 2019 Feb 19;20(4):890.

Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018 Jul;68(4):284–96.

Froyman W, Wynants L, Landolfo C, et al. Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population. Diagnostics (Basel). 2017 Jun 2;7(2):32.

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017 Feb;14(1):9-32.

Arania R, Windarti I. Karakteristik Pasien Kanker Ovarium di Rumah Sakit Dr. H. Abdul Moeloek Bandar Lampung Tahun 2009-2013. 2016.

Purwoko M. Hubungan Tingkat Pendidikan dan Pekerjaan dengan Tingkat Pengetahuan Mengenai Kanker Ovarium pada Wanita. Mutiara Medika: Jurnal Kedokteran dan Kesehatan. 2018;18(2).

Leung L, Lavoué J, Siemiatycki J, et al. Occupational environment and ovarian cancer risk. Occup Environ Med. 2023 Jul 10;80(9):489–97.

Xiong S, Mhawech-Fauceglia P, Tsao-Wei D, et al. Expression of the luteinizing hormone receptor (LHR) in ovarian cancer. BMC Cancer. 2019 Nov 15;19(1).

Hlaváč V, Holý P, Václavíková R, et al. Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy. Life Sci Alliance. 2022 Dec 1;5(12).

Bossart M, Plett H, Krämer B, et al. Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database. Arch Gynecol Obstet. 2023 Apr 1;307(4):1155–62.

Goyal LD, Kaur S, Kawatra K. Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer. J Ovarian Res. 2019;5(1):14.

Dhitayoni IA, Budiana ING. Profil Pasien Kanker Ovarium di Rumah Sakit Umum Pusat Sanglah Denpasar – Bali Periode Juli 2013 – Juni 2014. E-JURNAL MEDIKA. 2017;6(3):1–9.

Huang X, Shen C, Zhang Y, et al. Associations between TAB2 Gene Polymorphisms and Epithelial Ovarian Cancer in a Chinese Population. Dis Markers. 2019;2019:8012979.

Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):61-85.


  • There are currently no refbacks.

Copyright (c) 2024 Karina Rahmalia

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.